PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans

FEBS Journal

Volumn 275, Issue 13, 2008, Pages 3480-3493

  Dewpura, Thilina ^a   Raymond, Angela ^a   Hamelin, Josée ^b   Seidah, Nabil G ^b   Mbikay, Majambu ^a   Chrétien, Michel ^a   Mayne, Janice ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Cholesterol; Hypercholesterolemia; Kinase; PCSK9; Phosphoprotein

Indexed keywords

CASEIN KINASE; CELL PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PHOSPHOPROTEIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; SERINE;

ARTICLE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; EX VIVO STUDY; GOLGI COMPLEX; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIVER CELL; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN VARIANT; SITE DIRECTED MUTAGENESIS;

ANIMALS; CASEIN KINASES; CELL LINE; CRICETINAE; DNA, COMPLEMENTARY; GOLGI APPARATUS; HUMANS; HYPERCHOLESTEROLEMIA; LIVER; MASS SPECTROMETRY; MUTAGENESIS, SITE-DIRECTED; PEPTIDES; PHOSPHOPROTEINS; PHOSPHORYLATION; SERINE ENDOPEPTIDASES;

EID: 44949241428     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2008.06495.x     Document Type: Article

References (50)

1. Seidah NG, Khatib AM Prat A (2006) The proprotein convertases and their implication in sterol and/or lipid metabolism. Biol Chem 387, 871 877.
2. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A Chretien M (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 100, 928 933.
3. Seidah NG Prat A (2002) Precursor convertases in the secretory pathway, cytosol and extracellular milieu. Essays Biochem 38, 79 94.
4. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, Asselin MC, Hamelin J, Varret M, Allard D et al. (2004) NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 279, 48865 48875.
5. Benjannet S, Rhainds D, Hamelin J, Nassoury N Seidah NG (2006) The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem 281, 30561 30572.
6. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE Horton JD (2006) Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 116, 2995 3005.
7. Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, Cohen JC Hobbs HH (2006) Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 79, 514 523.
8. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA Horton JD (2005) Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA 102, 5374 5379.
9. Maxwell KN Breslow JL (2004) Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci USA 101, 7100 7105.
10. Maxwell KN, Fisher EA Breslow JL (2005) Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA 102, 2069 2074.
11. Lambert G (2007) Unravelling the functional significance of PCSK9. Curr Opin Lipidol 18, 304 309.
12. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC Hobbs HH (2007) Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 282, 18602 18612.
13. Qian YW, Schmidt RJ, Zhang Y, Chu S, Lin A, Wang H, Wang X, Beyer TP, Bensch WR, Li W et al. (2007) Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res 48, 1488 1498.
14. Nassoury N, Blasiole DA, Tebon Oler A, Benjannet S, Hamelin J, Poupon V, McPherson PS, Attie AD, Prat A Seidah NG (2007) The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 8, 718 732.
15. Cunningham D, Danley DE, Geoghegan KF, Griffor MC, Hawkins JL, Subashi TA, Varghese AH, Ammirati MJ, Culp JS, Hoth LR et al. (2007) Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 14, 413 419.
16. Naoumova RP, Tosi I, Patel D, Neuwirth C, Horswell SD, Marais AD, van Heyningen C Soutar AK (2005) Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol 25, 2654 2660.
17. Timms KM, Wagner S, Samuels ME, Forbey K, Goldfine H, Jammulapati S, Skolnick MH, Hopkins PN, Hunt SC Shattuck DM (2004) A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 114, 349 353.
18. Fisher TS, Lo Surdo P, Pandit S, Mattu M, Santoro JC, Wisniewski D, Cummings RT, Calzetta A, Cubbon RM, Fischer PA et al. (2007) Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem 282, 20502 20512.
19. Kwon HJ, Lagace TA, McNutt MC, Horton JD Deisenhofer J (2008) Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA 105, 1820 1825.
20. Cohen JC, Boerwinkle E, Mosley TH Jr. Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354, 1264 1272.
21. Scartezini M, Hubbart C, Whittall RA, Cooper JA, Neil AH Humphries SE (2007) The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. Clin Sci (Lond) 113, 435 441.
22. Mayne J, Raymond A, Chaplin A, Cousins M, Kaefer N, Gyamera-Acheampong C, Seidah NG, Mbikay M, Chretien M Ooi TC (2007) Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem Biophys Res Commun 361, 451 456.
23. Hooper AJ, Marais AD, Tanyanyiwa DM Burnett JR (2006) The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 193, 445 448.
24. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G Konrad RJ (2008) Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 49, 394 398.
25. Price PA, Rice JS Williamson MK (1994) Conserved phosphorylation of serines in the Ser-X-Glu/Ser(P) sequences of the vitamin K-dependent matrix Gla protein from shark, lamb, rat, cow, and human. Protein Sci 3, 822 830.
26. Homer VM, Marais AD, Charlton F, Laurie AD, Hurndell N, Scott R, Mangili F, Sullivan DR, Barter PJ, Rye KA et al. (2008) Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis 196, 659 666.
27. Graham ME, Kilby DM, Firth SM, Robinson PJ Baxter RC (2007) The in vivo phosphorylation and glycosylation of human insulin-like growth factor binding protein-5. Mol Cell Proteomics 6, 1392 1405.
28. Craig AG, Hoeger CA, Miller CL, Goedken T, Rivier JE Fischer WH (1994) Monitoring protein kinase and phosphatase reactions with matrix-assisted laser desorption/ionization mass spectrometry and capillary zone electrophoresis: comparison of the detection efficiency of peptide-phosphopeptide mixtures. Biol Mass Spectrom 23, 519 528.
29. Tibaldi E, Arrigoni G, Brunati AM, James P Pinna LA (2006) Analysis of a sub-proteome which co-purifies with and is phosphorylated by the Golgi casein kinase. Cell Mol Life Sci 63, 378 389.
30. Christensen B, Nielsen MS, Haselmann KF, Petersen TE Sorensen ES (2005) Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J 390, 285 292.
31. Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega GL, Cohen JC Hobbs HH (2006) A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 78, 410 422.
32. Coverley JA, Martin JL Baxter RC (2000) The effect of phosphorylation by casein kinase 2 on the activity of insulin-like growth factor-binding protein-3. Endocrinology 141, 564 570.
33. Huber SC Hardin SC (2004) Numerous posttranslational modifications provide opportunities for the intricate regulation of metabolic enzymes at multiple levels. Curr Opin Plant Biol 7, 318 322.
34. Jellinek DA, Chang AC, Larsen MR, Wang X, Robinson PJ Reddel RR (2000) Stanniocalcin 1 and 2 are secreted as phosphoproteins from human fibrosarcoma cells. Biochem J 350 (Pt 2 453 461.
35. 2 by MNK1-related protein kinases. J Biol Chem 275, 37542 37551.
36. Kohlstedt K, Shoghi F, Muller-Esterl W, Busse R Fleming I (2002) CK2 phosphorylates the angiotensin-converting enzyme and regulates its retention in the endothelial cell plasma membrane. Circ Res 91, 749 756.
37. Jones BG, Thomas L, Molloy SS, Thulin CD, Fry MD, Walsh KA Thomas G (1995) Intracellular trafficking of furin is modulated by the phosphorylation state of a casein kinase II site in its cytoplasmic tail. EMBO J 14, 5869 5883.
38. Jones JI, D'Ercole AJ, Camacho-Hubner C Clemmons DR (1991) Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects on affinity for IGF-I. Proc Natl Acad Sci USA 88, 7481 7485.
39. Quirk PG, Patchell VB, Colyer J, Drago GA Gao Y (1996) Conformational effects of serine phosphorylation in phospholamban peptides. Eur J Biochem 236, 85 91.
40. Hampton EN, Knuth MW, Li J, Harris JL, Lesley SA Spraggon G (2007) The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci USA 104, 14604 14609.
41. Piper DE, Jackson S, Liu Q, Romanow WG, Shetterly S, Thibault ST, Shan B Walker NP (2007) The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure 15, 545 552.
42. Berge KE, Ose L Leren TP (2006) Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol 26, 1094 1100.
43. Fasano T, Cefalu AB, Di Leo E, Noto D, Pollaccia D, Bocchi L, Valenti V, Bonardi R, Guardamagna O, Averna M et al. (2007) A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol 27, 677 681.
44. Ding K, McDonough SJ Kullo IJ (2007) Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species. PLoS ONE 2, e1098.
45. Li J, Tumanut C, Gavigan JA, Huang WJ, Hampton EN, Tumanut R, Suen KF, Trauger JW, Spraggon G, Lesley SA et al. (2007) Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem J 406, 203 207.
46. McNutt MC, Lagace TA Horton JD (2007) Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem 282, 20799 20803.
47. Fisher TS, Lo Surdo P, Pandit S, Mattu M, Santoro JC, Wisniewski D, Cummings RT, Calzetta A, Cubbon RM, Fischer PA et al. (2007) PCSK9-dependent LDL receptor regulation: effects of pH and LDL. J Biol Chem 282, 20502 20512.
48. Lopez D (2008) PCSK9: an enigmatic protease. Biochim Biophys Acta 1718, 184 191.
49. Elagoz A, Benjannet S, Mammarbassi A, Wickham L Seidah NG (2002) Biosynthesis and cellular trafficking of the convertase SKI-1/S1P: ectodomain shedding requires SKI-1 activity. J Biol Chem 277, 11265 11275.
50. Chowdhury PS, Gallo M Pastan I (2001) Generation of high titer antisera in rabbits by DNA immunization. J Immunol Methods 249, 147 154.